Oncotarget

Research Papers:

Adenovirus-mediated downregulation of the ubiquitin ligase RNF8 sensitizes bladder cancer to radiotherapy

Mei-Jun Zhao, Yan-Feng Song, Hai-Tao Niu, Ying-Xia Tian, Xu-Guang Yang, Kun Xie, Yu-Hong Jing and De-Gui Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:8956-8967. https://doi.org/10.18632/oncotarget.6909

Metrics: PDF 923 views  |   HTML 1203 views  |   ?  


Abstract

Mei-Jun Zhao1,*, Yan-Feng Song1,*, Hai-Tao Niu3,*, Ying-Xia Tian1,2,*, Xu-Guang Yang1, Kun Xie1, Yu-Hong Jing1 and De-Gui Wang1

1 Department of Anatomy and Histology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

2 Department of Internal Medicine, Gansu Provincial Academic Institute for Medical Research, Lanzhou, China

3 Department of Urology, Affiliated Hospital of Qingdao University, Qingdao, China

* These authors have contributed equally to this work

Correspondence to:

De-Gui Wang, email:

Keywords: bladder cancer, adenovirus, RNF8, radiotherapy, gene therapy

Received: August 24, 2015 Accepted: January 04, 2016 Published: January 13, 2016

Abstract

The ubiquitin ligase RNF8 promotes the DNA damage response (DDR). We observed that the expression of RNF8 was increased in bladder cancer cells and that this change in RNF8 expression could be reversed by adenovirus-mediated shRNA treatment. Moreover, we found that RNF8 knockdown sensitized bladder cancer cells to radiotherapy, as demonstrated by reduced cell survival. Additionally, the absence of RNF8 induced a high rate of apoptosis and impaired double-strand break repair signaling after radiotherapy. Furthermore, experiments on nude mice showed that combining shRNF8 treatment with radiotherapy suppressed implanted bladder tumor growth and enhanced apoptotic cell death in vivo. Altogether, our results indicated that RNF8 might be a novel target for bladder cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6909